News Frequency Names Advisory Board to Guide Remyelination Work for MS Frequency Names Advisory Board to Guide Remyelination Work for MS Aiming to move small molecule, reported to aid myelin sheath repair, into trials by Patricia Inacio, PhD | December 20, 2022 Share this article: Share article via email Copy article link Frequency Therapeutics has established a clinical advisory board, with experts across neuroscience fields, to help guide its small molecule treatment candidate for remyelination inĀ multiple sclerosis (MS) into clinical testing. The company is planning to initiate a first trial of the molecule, designed to boost remyelination ā the repair of the myelin sheathĀ that is progressively lost in MS ā in the second half of 2023. āWhile a number of approved drugs are highly effective in preventing new inflammatory lesions, stopping gradual neurodegeneration and gradual clinical worsening remain the greatest areas of unmet need,ā Richard Rudick, MD, a member of Frequency’s Remyelination Clinical Advisory Board, said in a company press release. Recommended Reading February 25, 2022 News by Marisa Wexler, MS #ACTRIMS2022 ā Blocking Fibulin-2 Protein May Increase Remyelination Chance to develop ‘entirely new therapy to address remyelination’ The myelin sheath is a fatty substance that covers nerve fibers to help them send electrical signals more efficiently. Inflammatory attacks due to MS damage this sheath, affecting nerve cell communication and causing a range of disease symptoms. While myelin can be repaired or replaced by myelin-producing cells called oligodendrocytes, this process tends to be less than optimal in MS, due to factors that include ongoing inflammation and aging. Frequency is leveraging its Progenitor Cell Activation (PCA) approach to harnesses the power of the bodyās innate regenerative potential to repair tissues and restore their function. Its MS program aims to develop novel, small-molecule therapeutics that temporarily activate immature oligodendrocyte progenitor cells (OPCs) and turn them into mature, myelin-making oligodendrocytes. This is expected to improve myelin repair and potentially halt, or even reverse, MS progression. The company did not disclose the treatment target identified and validated by its scientists. Rather, its reported on its website that preclinical studies showed its lead compound, FREQ-162, triggered the maturation of progenitor cells into oligodendrocytes. These new cells were found to be capable of producing myelin in a preclinical model of demyelination. āSupported by impressive preclinical data generated to date, Frequency has an opportunity to develop an entirely new therapy to address remyelination, and potentially provide those with MS with a first-in-class medicine with the hope of repairing damage caused by this challenging disease,ā said Rudick, a former director of the Mellon Center at theĀ Cleveland Clinic. Rudick had “key roles” in the development of two approved MS therapies,Ā Avonex (interferon beta-1a) and Tysabri (natalizumab), the release stated. The Remyelination Clinical Advisory BoardĀ also includes Laura J. Balcer, MD, whose career has been focused on the development of visual outcome measures for MS clinical trials; Alasdair Coles, PhD, who was involved in the development of Lemtrada (alemtuzumab); and Steven Galetta, MD, with expertise in clinical, radiological, and research aspects of MS. āWe are grateful to have the opportunity to work with world-class leaders in neurology and multiple sclerosis on our newly formed Clinical Advisory Board. Their expertise developing transformative medicines for serious neurological diseases will be invaluable as we advance our remyelination program into clinical studies,ā said Christopher Loose, PhD, Frequencyās chief scientific officer. James Rothman, PhD, a winner of theĀ Nobel Prize in Medicine in 2013, will also join the company’s PCA Regenerative Medicine Advisory Board. āDr. Rothman is among the preeminent cell biologists in the world and his scientific insights will help inform our efforts for optimally applying our regenerative medicine technology for the treatment of human disease,” Loose added. Print This Page About the Author Patricia Inacio, PhD Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship. Tags oligodendrocytes, remyelination therapy
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program